We did not include CSF biomarkers for non-beta-amyloid/tau neurodegenerative processes (e.g., a-synuclein, phosphorylated TDP-43 levels) as they are less mature, and accounting for them may help explain variability across centers and AD stages. This evidence concerns the gene MAPT and Alzheimer disease.